Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...

If you value the S&P 500 on earnings, its price-to-earnings ratio of 28 is also significantly above its historical norms. The Vanguard FTSE Developed Markets ETF trades at 15.5 times earnings today, a ...

If found to be lacking adequate compliance systems, Moderna could ultimately be suspended or expelled from the Association of ...